anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
==== Information about donor ==== In the United States, sperm banks maintain lists of donors which provide basic information about the donor such as racial origin, skin color, height, weight, color of eyes, and blood group. Qualities that potential recipients typically prefer in donors include the donors being tall, college educated, and with a consistently high sperm count. A review came to the result that 68% of donors had given information to the clinical staff regarding physical characteristics and education but only 16% had provided additional information such as hereditary aptitudes and temperament or character.
===== MeSH D08.811.682.662 – oxidoreductases acting on ch-nh group donors ===== MeSH D08.811.682.662.162 – dihydropteridine reductase MeSH D08.811.682.662.171 – FMN reductase MeSH D08.811.682.662.217 – methylenetetrahydrofolate dehydrogenase (nad+) MeSH D08.811.682.662.253 – methylenetetrahydrofolate dehydrogenase (nadp) MeSH D08.811.682.662.290 – methylenetetrahydrofolate reductase (nadph2) MeSH D08.811.682.662.582 – oxidoreductases, n-demethylating MeSH D08.811.682.662.582.276 – aminopyrine n-demethylase MeSH D08.811.682.662.582.338 – cytochrome p-450 cyp2e1 MeSH D08.811.682.662.582.353 – cytochrome p-450 cyp3a MeSH D08.811.682.662.582.361 – dihydropteridine reductase MeSH D08.811.682.662.582.369 – dimethylglycine dehydrogenase MeSH D08.811.682.662.582.400 – ethylmorphine-n-demethylase MeSH D08.811.682.662.582.550 – sarcosine dehydrogenase MeSH D08.811.682.662.582.700 – sarcosine oxidase MeSH D08.811.682.662.640 – proline oxidase MeSH D08.811.682.662.680 – pyridoxamine-phosphate oxidase MeSH D08.811.682.662.693 – 1-pyrroline-5-carboxylate dehydrogenase MeSH D08.811.682.662.695 – pyrroline carboxylate reductases MeSH D08.811.682.662.750 – saccharopine dehydrogenases MeSH D08.811.682.662.825 – tetrahydrofolate dehydrogenase
=== Xander Lindt === Xander Lindt (Gustav Lindh) is a cocky young heir of the Lindt chocolate empire, and a member of Henry's entourage. He repeatedly demeans Yasmin after she rejects his sexual advances at a Swiss climate conference.
Sources: en.wikipedia.org
=== Bossa and Vertigo === By September 2017, Faliszek had joined London-based Bossa Studios, and led Bossa's new Seattle-based studio. He was working on an unannounced cooperative game that is "trying to do something new in the narrative space using [artificial intelligence]". In May 2018, Faliszek announced he had also joined the board of advisers for Vertigo Games, and will help support a virtual reality title they are currently developing. After about a year at Bossa, Faliszek and Bossa agreed that what Faliszek had planned was not working out, in part due to his envisioned game not being the type of product Bossa had worked on before, and Faliszek left the company early in 2019. By March 2019, he founded a new studio, Stray Bombay Company, along with Riot Games' Kimberly Voll, in essence to continue the development of the cooperative title. Faliszek had previously met Voll around 2012 while Valve was exploring the VR space, and had helped Voll get Radial Games Fantastic Contraption as a SteamVR launch title. Faliszek found Voll's focus on player interaction a key part of his idea for the cooperative game. Stray Bombay was backed financially by both Riot and Upfront Ventures. The company's first game is The Anacrusis, which was released via early access in January 2022, and fully launched December 5th, 2023. Starting around 2023, Faliszek began to post TikToks and YouTube videos about his time at Valve, experiences in the games industry, and his views on game design. He would make a video about Stop Killing Games, disagreeing with the movement.
Taylor was not keen on Thomas taking another trip to the United States, and thought that if he had a permanent address in London he would be able to gain steady work there. She bought a property, 54 Delancey Street, in Camden Town, and in late 1951 Thomas and Caitlin lived in the basement flat. Thomas would describe the flat as his "London house of horror" and did not return there after his 1952 tour of America.
== Early life and education == Born in Thrissur, Kerala, Kallingal began practising dance at age 3. She was born to K. R. Rajan and Leenabhai at the Ayyanthole Kallingal family home in Thrissur district. She studied at Stanes Anglo-Indian School in Coonoor up to class 5, and completed her schooling at Chinmaya Vidyalaya in Thrissur, graduating in 2001. She holds a bachelor's degree in Journalism from Christ University, Bengaluru. She is also trained in Taekwondo, Chao (a Manipuri martial art), and Kalari. She joined the Bengaluru-based contemporary dance company Nritarutya after graduation and performed with the company on national and international stages before transitioning to acting. She was a semi-finalist on the Asianet reality show Vodafone Thakadhimi, and later participated in the Miss Kerala 2008 beauty pageant, placing first runner-up to Shree Thulasi in a tie-breaker.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.